Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2005
09/01/2005US20050192306 Pyrimidine derivatives as selective inhibitors of COX-2
09/01/2005US20050192304 Rho-kinase inhibitors
09/01/2005US20050192300 Pyrimidine compounds
09/01/2005US20050192284 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processed for its manufacture and its use
09/01/2005US20050192274 Combinations of drugs for the treatment of neoplastic disorders
09/01/2005US20050192266 Including vanadocene dihalides, bis(methylcyclopentadienyl), vanadocene diazide, vanadocene dicyanide, vanadocene dioxycyanate, vanadocene dithiocyanate, vanadocene diselenocyanate, vanadocene ditriflate, vanadocene monochloro oxycyanate, vanadocene monochloro acetonitrilo tetrachloro ferrate
09/01/2005US20050192235 Compositions and methods for treating or preventing diseases of body passageways
09/01/2005US20050192227 Method for reducing the risk of cancer
09/01/2005US20050191747 Recombinant bovine immunodeficiency virus based gene transfer system
09/01/2005US20050191713 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
09/01/2005US20050191696 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products
09/01/2005US20050191695 Documentation means for repertoires of NKR immunoreceptors and/or activatory or non-inhibitory immunoreceptor counterparts of NKR immunoreceptors
09/01/2005US20050191690 Membrane proteins for identifying modulators for prevention and treatment of infection, cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory and metabolic disorders
09/01/2005US20050191649 Identifying mutation in oligoadenylate synthetase gene (OAS1); identifying modulators for prevention and treatment of cell proliferative, nervous system and diabetic disorders
09/01/2005US20050191641 Nucleotide sequences coding hydrolase for use as tool in identifying modulators for prevention and treatment of digestion, coagulation, diabetic, cell proliferative, urogenital, eating and nervous system gynecological disorders
09/01/2005US20050191367 Administering a therapeutically effective amount of arsenic compounds, optionally along with other non-arsenic therapeutic agents, to a mammal for treating solid tumors
09/01/2005US20050191354 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
09/01/2005US20050191345 Temperature-sensitive liposomal formulation
09/01/2005US20050191323 Pharmaceutical formulations comprising paclitaxel, derivatives and pharmaceutically acceptable salts thereof
09/01/2005US20050191306 Cancerous disease modifying antibodies
09/01/2005US20050191305 Cancerous disease modifying antibodies
09/01/2005US20050191301 Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
09/01/2005US20050191300 Immunotherapy of autoimmune disorders using antibodies which target B-cells
09/01/2005US20050191277 Methods of treating various cancers using melanoma differentiation associated protein-7
09/01/2005US20050191275 Method for short-term and long-term drug dosimetry
09/01/2005DE102004038076A1 Use of annexin A3, or other proteins, as diagnostic markers for cancer, especially of the prostate, also use of modulators of these markers for treating cancer
09/01/2005DE102004003030A1 Composition containing a dihydroanthracene-disulfonic acid derivative, useful for treating inflammation of internal organs, e.g. ulcers, and cancer
09/01/2005CA2788707A1 Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
09/01/2005CA2557433A1 Quinazoline derivatives and therapeutic use thereof
09/01/2005CA2557154A1 Anticancer agent containing bl-angiostatin
09/01/2005CA2556589A1 4-substituted piperidine derivatives
09/01/2005CA2556027A1 Monoclonal antibodies that specifically block biological activity of a tumor antigen
09/01/2005CA2555984A1 Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
09/01/2005CA2555694A1 Anti-epcam immunoglobulins
09/01/2005CA2555417A1 Inhibition of fgf signaling
09/01/2005CA2555236A1 Methods of modulating cytokine activity; related reagents
09/01/2005CA2526905A1 Composition for nkt cell activation
09/01/2005CA2498966A1 Novel pyrazole analogs acting on cannabinoid receptors
08/2005
08/31/2005EP1568779A1 HSV strains for the oncolytic treatment of cancer
08/31/2005EP1568775A1 Cancer-associated gene
08/31/2005EP1568772A2 Human growth hormone variants
08/31/2005EP1568771A2 Human growth hormone variants
08/31/2005EP1568708A2 Methods and medical uses of nucleic acids encoding a TRAF inhibitor
08/31/2005EP1568704A1 Novel 2' ,5' -oligoadenylic acid analogues
08/31/2005EP1568702A1 Palladium complexes with heterocyclic ligands
08/31/2005EP1568699A1 1,3-dihydroimidazole fused-ring compound
08/31/2005EP1568697A1 1,3-benzothiazinone derivatives, process for producing the same and use thereof
08/31/2005EP1568381A1 Remedy for hormone-dependent cancer
08/31/2005EP1568379A1 Medicinal preparation having chemotherapeutic encapsulated therein
08/31/2005EP1568377A1 Cysteine protease inhibitor
08/31/2005EP1568373A2 Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
08/31/2005EP1568360A1 Liposome
08/31/2005EP1567644A2 Tissue specific genes and gene clusters
08/31/2005EP1567641A2 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
08/31/2005EP1567550A2 Peptide conjugate useful for cell nucleus molecular imaging and tumor therapy
08/31/2005EP1567527A1 Condensed pyrazolo derivatives
08/31/2005EP1567524A1 Thia-epothilone derivatives for the treatment of cancer
08/31/2005EP1567522A1 Pyrimidine compounds
08/31/2005EP1567515A2 Novel lapachone compounds and methods of use thereof
08/31/2005EP1567507A1 1,2,3- triazole amide derivatives as cytokine inhibitors
08/31/2005EP1567506A2 Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
08/31/2005EP1567476A2 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
08/31/2005EP1567181A2 Methods for treatment of helicobacter pylori-associated disorders
08/31/2005EP1567160A2 Method of treatment of myocardial infarction
08/31/2005EP1567158A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
08/31/2005EP1567154A2 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
08/31/2005EP1567150A1 Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics
08/31/2005EP1461063A4 Treatment of glioblastoma with thymosin-alpha 1
08/31/2005EP1430057B1 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido 1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo 1,2-a]pyrimidin-5(1h)one derivatives
08/31/2005EP1397359B1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
08/31/2005EP1366038B1 Cdk-1 inhibitor oxindoles and the application thereof in therapeutics
08/31/2005EP1268445B1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
08/31/2005EP1244445B1 Use of azoles for preventing skin cancer due to radiation
08/31/2005EP1240168B1 Bicyclic inhibitors of glycogen synthase kinase 3
08/31/2005EP1224192B1 Half-sandwich ruthenium (ii) compounds comprising nitrogen containing ligands for treatment of cancer
08/31/2005EP1140809B1 New biphenyl and biphenyl-analogous compounds as integrin antagonists
08/31/2005EP1117424B1 Null igf for the treatment of cancer
08/31/2005EP1117297B1 Synthetic analogs of ecteinascidin-743
08/31/2005EP1095020B1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them
08/31/2005EP1076486B1 Culture of sessile marine animals
08/31/2005EP1069894B1 Spisulosine compounds having antitumour activity
08/31/2005EP0989973B1 Chalcones having antiproliferative activity
08/31/2005EP0973819B1 Non-antigenic branched polymer conjugates
08/31/2005EP0939653B1 Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
08/31/2005EP0786002B1 Intracellular isoform of the interleukin-1 receptor antagonist
08/31/2005EP0721345B1 Prostatic cancer vaccine
08/31/2005EP0721335B1 Mycophenolate mofetil high dose oral suspensions
08/31/2005CN1662664A Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
08/31/2005CN1662661A Method for detecting increased susceptibility to tumours
08/31/2005CN1662558A Antibodies specific for human cd22 and their therapeutic anddiagnostic uses
08/31/2005CN1662540A 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
08/31/2005CN1662539A [1, 4]diazocino [7, 8, 1-hi]indole derivatives as antipsychotic and antiobesity agents
08/31/2005CN1662534A 1, 2, 3, 4, 7, 8-hexahydro-6h-[1, 4]diazepino[6, 7, 1-1j]quinoline derivatives as antipsychotic and antiobesity agents
08/31/2005CN1662530A Azabicyclo-octane and nonane derivatives with DPP-IV inhibiting activity
08/31/2005CN1662529A Thiazole derivatives as phosphodiesterase IV inhibitors
08/31/2005CN1662513A 2-thioxothiazole derivative, method for preparing the same, and pharmaceutical composition containing the same
08/31/2005CN1662508A Compounds, compositions and methods
08/31/2005CN1662507A Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same
08/31/2005CN1662504A 2, 5-disubstituted 3-mercaptopentanoic acid
08/31/2005CN1662502A Cyanoguanidine produgs
1 ... 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 ... 2211